Annette Marian Doherty, 63San Diego, CA

6737410, May 18, 2004

Oct 4, 2000

09/678554

Annette Marian Doherty - Ann Arbor MI
Daniele Marie Leonard - Ann Arbor MI
Dennis Joseph McNamara - Ann Arbor MI
Kevon Ray Shuler - Chelsea MI

Warner-Lambert Company - Ann Arbor MI

C07K 506

514 19, 548344

The present invention provides compounds having the structure represented by Formula I: and methods of treating cancer, restenosis, atherosclerosis, or psoriasis or preventing restenosis, and a pharmaceutical composition comprising a compound of Formula I and a pharmaceutically acceptable carrier.

5482960, Jan 9, 1996

Nov 14, 1994

8/339381

Kent A. Berryman - Ann Arbor MI
Amy M. Bunker - Ypsilanti MI
Annette M. Doherty - Ann Arbor MI
Jeremy J. Edmunds - Ypsilanti MI

Warner-Lambert Company - Morris Plains NJ

A61K 3140
C07D20904

514414

Novel indole and indoline nonpeptide antagonists of endothelin I are described, as well as novel intermediates used in their preparation, methods for the preparation and pharmaceutical compositions of the same, which are useful in treating elevated levels of endothelin, essential renovascular malignant and pulmonary hypertension, cerebral infarction, cerebral ischemia, congestive heart failure and subarachnoid hemorrhage.

5691373, Nov 25, 1997

Feb 6, 1995

8/384083

Kent Alan Berryman - Ann Arbor MI
Annette Marian Doherty - Ann Arbor MI
Jeremy John Edmunds - Ypsilanti MI
William Chester Patt - Chelsea MI
Mark Stephen Plummer - Dexter MI
Joseph Thomas Repine - Ann Arbor MI

Warner-Lambert Company - Morris Plains NJ

A61K 3136
A61K 3138
A61K 3144
A61K 31535

514464

Novel nonpeptide antagonists of endothelin I are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in treating elevated levels of endothelin, acute and chronic renal failure, hypertension, myocardial infarction, myocardial ischemia, cerebral vasospasm, cerebral ischemia, cerebral infarction, cirrhosis, septic shock, congestive heart failure, endotoxic shock, subarachnoid hemorrhage, arrhythmias, asthma, preeclampsia, atherosclerotic disorders including Raynaud's disease and restenosis, angina, cancer, pulmonary hypertension, ischemic disease, gastric mucosal damage, hemorrhagic shock, ischemic bowel disease, stroke, benign prosthatic hyperplasia (BPH), and diabetes.

5071837, Dec 10, 1991

Nov 28, 1990

7/621138

Annette M. Doherty - Ann Arbor MI
Ila Sircar - Ann Arbor MI

Warner-Lambert Company - Morris Plains NJ

C07K 508
A61K 3702

514 18

The invention concerns certain orally active novel renin-inhibitory peptides which are useful for treating renin-associated hypertension, congestive heart failure, hyperaldosteronism, and glaucoma. It is also useful for treating diseases caused by retroviruses including HTLV-I, -II, and -III. Process for preparing the peptides, compositions containing them, and methods of using them are included. Also included is a diagnostic method which uses the compounds to determine the presence of renin-associated hypertension, congestive heart failure, or hyperaldosteronism.

5620981, Apr 15, 1997

May 3, 1995

8/433294

Clifton J. Blankley - Ann Arbor MI
Diane H. Boschelli - Plymouth MI
Annette M. Doherty - Ann Arbor MI
James M. Hamby - Ann Arbor MI
Sylvester Klutchko - Ann Arbor MI
Robert L. Panek - Canton MI

Warner-Lambert Company - Morris Plains NJ

A61K 31505
C07D48702

514258

6-Aryl pyrido[2,3-d]pyrimidine 7-imines, 7-ones, and 7-thiones are inhibitors of protein tyrosine kinases, and are thus useful in treating cellular proliferation mediated thereby. The compounds are especially useful in treating cancer, atherosclerosis, restenosis, and psoriasis.

5024994, Jun 18, 1991

Aug 17, 1988

7/233320

Annette M. Doherty - Ann Arbor MI
James P. Hudspeth - Newbury Park CA
James S. Kaltenbronn - Ann Arbor, MI
Joseph T. Repine - Ann Arbor MI
William H. Roark - Ann Arbor MI
Ila Sircar - Ann Arbor MI
Francis J. Tinney - Ann Arbor MI

Warner-Lambert Company - Morris Plains NJ

A61K 3702
C07K 500

514 18

The invention concerns novel renin-inhibitory peptides which are useful for treating renin-assocated hypertension, hyperaldosteronism, and congestive heart failure. Processes for preparing the peptides, compositions containing them and methods of using them are included. Also included is a diagnostic method which uses the compounds to determine the presence of renin-associated hypertension or hyperaldosteronism.

6017916, Jan 25, 2000

Jan 22, 1997

8/787423

Kent Alan Berryman - Ann Arbor MI
Annette Marian Doherty - Ann Arbor MI
Jeremy John Edmunds - Ypsilanti MI
William Chester Patt - Chelsea MI
Mark Stephen Plummer - Dexter MI
Joseph Thomas Repine - Ann Harbor MI

Warner-Lambert Company - Morris Plains NJ

A61K 31535
A61K 3138
A61K 31335

5142338

Novel nonpeptide antagonists of endothelin I are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in treating elevated levels of endothelin, acute and chronic renal failure, hypertension, myocardial infarction, myocardial ischemia, cerebral vasospasm, cerebral ischemia, cerebral infarction, cirrhosis, septic shock, congestive heart failure, endotoxic shock, subarachnoid hemorrhage, arrhythmias, asthma, preeclampsia, atherosclerotic disorders including Raynaud's disease and restenosis, angina, cancer, pulmonary hypertension, ischemic disease, gastric mucosal damage, hemorrhagic shock, ischemic bowel disease, stroke, benign prosthatic hyperplasia (BPH), and diabetes.

5663296, Sep 2, 1997

Jan 17, 1995

8/373911

Annette Marian Doherty - Ann Arbor MI
Brian Edward Kornberg - Ann Arbor MI
Sham Nikam - Ann Arbor MI

Warner-Lambert Company - Morris Plains NJ

A61K 3806

530331

Hydroxamate compounds of the following formula are disclosed: R--AA. sup. 3 --AA. sup. 4 --AA. sup. 5 --AA. sup. 6 --NH--OR. sup. 2 wherein AA. sup. 3 --AA. sup. 6 represent amino acid residues. The disclosed compounds are inhibitors of endothelin converting enzyme, and as such are useful for the treatment of disorders resulting from overproduction of endothelin, i. e. , acute and chronic renal failure, cyclosporin-A induced nephrotoxicity, hypertension, myocardial infarction, metabolic, endocrinological, neurological disorders, congestire heart failure, endotoxic shock and hemorrhagic shock, septic shock, subarachnoid hemorrhage, arrhythmias, asthma, preeclampsia, atherosclerotic disorders including Raynaud's disease, cerebral vasospasm, restenosis, angina, cancer, pulmonary hypertension, ischemic disease, gastric mucosal damage, ischemic bowel disease, and diabetes.